Crewe Advisors LLC Sells 79 Shares of Eli Lilly and Company (NYSE:LLY)

Crewe Advisors LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.2% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,452 shares of the company’s stock after selling 79 shares during the quarter. Crewe Advisors LLC’s holdings in Eli Lilly and Company were worth $1,315,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Blackhawk Capital Partners LLC. lifted its holdings in Eli Lilly and Company by 6.9% during the 2nd quarter. Blackhawk Capital Partners LLC. now owns 5,215 shares of the company’s stock worth $4,722,000 after purchasing an additional 335 shares during the last quarter. TrueMark Investments LLC acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $2,056,000. Highview Capital Management LLC DE boosted its position in shares of Eli Lilly and Company by 1.1% in the second quarter. Highview Capital Management LLC DE now owns 6,582 shares of the company’s stock valued at $5,959,000 after acquiring an additional 73 shares during the period. Nations Financial Group Inc. IA ADV grew its stake in shares of Eli Lilly and Company by 0.5% in the second quarter. Nations Financial Group Inc. IA ADV now owns 6,153 shares of the company’s stock valued at $5,571,000 after acquiring an additional 31 shares in the last quarter. Finally, Scott & Selber Inc. increased its position in Eli Lilly and Company by 0.7% during the second quarter. Scott & Selber Inc. now owns 2,134 shares of the company’s stock worth $1,932,000 after acquiring an additional 15 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Barclays increased their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Bank of America increased their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. BMO Capital Markets raised their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price objective for the stock from $725.00 to $1,025.00 in a research report on Monday, August 12th. Two research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $961.76.

Eli Lilly and Company Trading Up 2.1 %

Shares of Eli Lilly and Company stock traded up $19.82 during midday trading on Friday, reaching $960.02. The company had a trading volume of 2,456,992 shares, compared to its average volume of 3,070,253. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The firm has a market cap of $912.41 billion, a PE ratio of 141.39, a P/E/G ratio of 1.81 and a beta of 0.41. The stock has a fifty day moving average price of $891.13 and a 200 day moving average price of $819.99. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the transaction, the insider now owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the sale, the insider now owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold a total of 1,097,883 shares of company stock valued at $972,022,568 in the last 90 days. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.